Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide

Brain Research

Volumn 1041, Issue 1, 2005, Pages 48-55

  Freezer, Alexander ^a   Salem, Abdallah ^a   Irvine, Rodney J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

3,4 Methylenedioxymethamphetamine; Ecstasy; Moclobemide; Monoamine oxidase A inhibitor; para methoxyamphetamine

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 METHOXYAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; MOCLOBEMIDE; SEROTONIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; MALE; MICRODIALYSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL;

EID: 15944391698     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2005.01.093     Document Type: Article

References (34)

1. W.P. Burkard, M. Da Prada, H.H. Keller, R. Kettler, and W. Haefely Pre-clinical pharmacology of moclobemide: a review of published studies Br. J. Psychiatry 155 1989 84 88
2. D.G. Caldicott, N.A. Edwards, A. Kruys, K.P. Kirkbride, D.N. Sims, R.W. Byard, M. Prior, and R.J. Irvine Dancing with "death": p-methoxyamphetamine overdose and its acute management J. Toxicol., Clin. Toxicol. 41 2003 143 154
3. M.I. Colado, T.K. Murray, and A.R. Green 5-HT lose in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine Br. J. Pharmcol. 108 1993 582 583
4. A. Colzi, F. D'Agostini, A.M. Cesura, E. Borroni, and M. Da Prada Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo J. Pharmacol. Exp. Ther. 265 1992 103 111
5. R. Dafters, and E. Lynch Persistent loss of thermoregulation in rat induced by 3,4 methyl-enedioxymethamphetamine (MDMA or "ecstasy") but not by fenfluramine Psychopharmacology 138 1998 207 212
6. M. Da Prada, R. Kettler, H.H. Keller, W.P. Burkard, D. Muggli-Maniglio, and W.E. Haefely Neurochemical profile of moclobemide, a short acting and reversible inhibitor of monoamine oxidase type A J. Pharmacol. Exp. Ther. 248 1989 400 414
7. L.C. Daws, R.J. Irvine, P.D. Callaghan, N.P. Toop, J.M. White, and F. Bochner Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenemethamphetamine in the rat Prog. Neuro-Psychopharmacol. Biol. Psychiatry 24 2000 955 977
8. L. Degenhardt, B. Barker, and L. Topp Patterns of ecstasy use in Australia: findings from a national household survey Addiction 99 2004 187 195
9. R.A. Ener, S.B. Meglathery, W.A. Van Decker, and R.M. Gallagher Serotonin syndrome and other serotonergic disorders Pain Med. 4 2003 63 74
10. B. Gough, S.Z. Imam, B. Blough, W. Slikker, and S.F. Ali Comparative effects of substituted amphetamines (PMA, MDMA and METH) on monoamines in rat caudate: a microdialysis study Ann. N. Y. Acad. Sci. 965 2002 410 420
11. D.G. Grahame-Smith Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and l-tryptophan J. Neurochem. 18 1971 1053 1066
12. A.R. Green, A.O. Mechan, J.M. Elliott, E. O'Shea, and M.I. Colado The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") Pharmacol. Rev. 55 2003 463 508
13. G.A. Gudelsky, and J.F. Nash Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine-implications for serotonin-dopamine interactions J. Neurochem. 66 1996 243 249
14. W. Haefely, W.P. Burkard, A.M. Cesura, R. Kettler, H.P. Lorez, J.R. Martin, J.G. Richards, R. Scherschlicht, and M. Da Prada Biochemistry and pharmacology of moclobemide, a prototype RIMA Psychopharmacology 106 1992 S6 S14
15. W. Haefely, W.P. Burkard, A.M. Cesura, R. Kettler, H.P. Lorez, J.R. Martin, J.G. Richards, R. Scherschlicht, and M. Da Prada Pharmacology of moclobemide Clin. Neuropharmacol. 16 1993 S8 S18
16. K.M. Hegadoren, M.T. Martin-Iverson, and G.B. Baker Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methlenedioxy analogues of amphetamine Psychopharmacology 118 1995 295 304
17. M. Iurlo, G. Leone, B. Schilström, L. Linnér, G. Nomikos, P. Hertel, B. Silvestrini, and H. Svensson Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition Psychopharmacology 159 2001 98 104
18. M.T. Lin, H.J. Tsay, W.H. Su, and F.Y. Chueh Changes in extracellular serotonin in rat hypothalamus affect thermoregulatory function Am. J. Physiol. 274 1998 R1260 R1267
19. L.H. Ling, C. Marchant, N.A. Buckley, M. Prior, and R.J. Irvine Poisoning with the recreational drug paramethoxyamphetamine Med. J. Aust. 174 2001 453 455
20. E.T. Leonardi, and E.C. Azmitia MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac) Neuropsychopharmacology 10 1994 231 238
21. A.G. Molloy, and J.L. Waddington Assessment of grooming and other behavioural responses to the D-1 dopamine receptor agonist SK and F 38393 and its R- and S-enantiomers in the intact adult rat Psychopharmacology 92 1987 164 168
22. J.F. Nash, H.Y. Meltzer, and G.A. Gudelsky Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine J. Pharmcol. Exp. Ther. 245 1988 873 879
23. D.E. Nichols, M. Ilhan, and J.P. Long Comparison of cardiovascular, hyperthermic and toxic effects of para-methoxyamphetamine (PMA) and 3,4-methylene dioxyamphetamine (MDA) Arch. Int. Pharmacodyn. Ther. 214 1975 133 140
24. S. Oie, T.W. Guentert, L. Tolentino, and G. Hermodsson Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats J. Pharm. Pharmacol. 44 1992 413 418
25. E.D. O'Loinsigh, G. Boland, J.P. Kelly, and K.M. O'Boyle Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat Prog. Neuro-Psychopharmacol. Biol. Psychiatry 25 2001 621 638
26. E. O'Shea, R. Granados, B. Esteban, M.I. Colado, and A.R. Green The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose frequency of administration of MDMA ("ecstasy") Neuropharmacology 37 1998 919 926
27. A.C. Parrott Recreational ecstasy/MDMA, the serotonin syndrome and serotonergic neurotoxicity Pharmacol. Biochem. Behav. 71 2002 837 844
28. G. Paxinos, and C. Watson The rat brain in stereotaxic coordinates 2nd ed. 1986 Academic Press Sydney
29. M.C. Scorza, C. Carrau, R. Silveira, G. Zapata-Torres, B.K. Cassels, and M. Reyes-Parada Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives Biochem. Pharmacol. 54 1997 1361 1369
30. L.J. Spanos, and B.K. Yamamoto Acute and subchronic effects of methylenedioxymethamphetamine[±MDMA] on locomotion and the serotonin syndrome behaviour in the rat Pharmacol. Biochem. Behav. 32 1989 835 840
31. L.F. Tseng, R.J. Hitzemen, and H.H. Loh Comparative effects of dl-p-methoxyamphetamine and d-amphetamine on catecholamine release and reuptake in vitro J. Pharmacol. Exp. Ther. 189 1974 708 715
32. E. Vuori, J.A. Henry, I. Ojanperä, R. Nieminen, T. Savolainen, P. Wahlsten, and M. Jäntti Death following ingestion of MDMA (ecstasy) and moclobemide Addiction 98 2003 365 368
33. M. Yamada, and H. Yasuhara Clinical pharmacology of MAO inhibitors: safety and future Neurotoxicology 25 2004 215 221
34. B.K. Yamamoto, J.F. Nash, and G.A. Gudelsky Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and g-aminobutyric acid in the substantia nigra J. Pharmacol. Exp. Ther. 273 1995 1063 1070